文章摘要
赵乂.线粒体解偶联蛋白 2在肝癌组织中的表达及其与紫杉醇化疗耐药的关系[J].安徽医药,2020,24(8):1620-1623.
线粒体解偶联蛋白 2在肝癌组织中的表达及其与紫杉醇化疗耐药的关系
The clinical significance of UCP2 expression in hepatocellular carcinoma and its relationship with resistance to paclitaxel chemotherapy
  
DOI:10.3969/j.issn.1009?6469.2020.08.037
中文关键词: 肝肿瘤  抗药性,肿瘤  线粒体膜转运蛋白质类  线粒体解偶联蛋白 2  紫杉醇
英文关键词: Liver neoplasms  Drug resistance,neoplasm  Mitochondrial membrane transport proteins  Mitochondrial uncou? pling protein 2  Paclitaxel
基金项目:
作者单位
赵乂 仪陇县人民医院肿瘤内科四川南充 637600 
摘要点击次数: 1569
全文下载次数: 555
中文摘要:
      目的研究线粒体解偶联蛋白 2(uncoupling protein2,UCP2)在肝癌组织中表达的临床意义及其与紫杉醇化疗耐药的关系。方法选取 2012年 2月至 2013年 2月在仪陇县人民医院住院的肝癌病人 120例,比较不同病理资料的 UCP2水平,通过对病人展开为期 5年的随访,比较不同预后及紫杉醇的耐药情况。结果肝癌组织 UCP2阳性表达 72例,表达率 60.00%,高于癌旁组织的 12例,表达率 10.00%,不同组织分化、淋巴结转移、 TNM分期、生存情况的 UCP2水平及紫杉醇耐药情况比较,均差异有统计学意义(P<0.05);不同组织分化、淋巴结转移、 TNM分期、生存情况及 UCP2水平均为紫杉醇耐药的独立危险因素, UCP2水平与紫杉醇耐药情况呈正相关(P<0.05)。结论 UCP2阳性肝癌病人紫杉醇耐药性较高,生存情况较差,可作为病人预后评估的依据。
英文摘要:
      Objective To explore the clinical significance of uncoupling protein 2(UCP2)expression in hepatocellular carcinoma and its relationship with resistance to paclitaxel chemotherapy.Methods A hundred and twenty patients with hepatocellular carci? noma hospitalized in People’s Hospital of Yilong County from February 2012 to February 2013 were selected as the research sub?jects.UCP2 levels of patients with different pathological data were compared after admission.And the patients were followed up forfive years to compare prognoses and paclitaxel resistance.Results The positive expression of UCP2 in hepatocellular carcinoma tis? sues was significantly higher than that in normal liver tissues[72 cases(60.00%)vs. 12 cases(10.00%)] .There were significant differences in UCP2 levels and paclitaxel resistance in different tissue differentiation,lymph node metastasis,TNM staging,and sur? vival(P<0.05).Different tissue differentiation,lymph node metastasis,TNM staging,survival and UCP2 level were independent risk factors for paclitaxel resistance,and UCP2 level was positively correlated with paclitaxel resistance(P<0.05).Conclusion The patients with UCP2 positive hepatocellular carcinoma have high resistance to paclitaxel and poor survival,which can be used as a basis for prognosis evaluation.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮